Tokyo Tape
Sign in
← Nipro

Quarterly report · Q2

8086.TEDINET S100PL3A
Period2022-04-01 → 2022-09-30
Filed2022-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 49
MetricValuePeriodScopeSource row
Revenue¥260.3bn2022-04-01 → 2022-09-30Cons.Net sales
Revenue¥494.8bn2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥242.1bn2021-04-01 → 2021-09-30Cons.Net sales
Operating income¥6.4bn2022-04-01 → 2022-09-30Cons.Operating income
Operating income¥12.9bn2021-04-01 → 2021-09-30Cons.Operating income
Ordinary income¥11.6bn2022-04-01 → 2022-09-30Cons.Ordinary income
Ordinary income¥27.6bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥12.4bn2021-04-01 → 2021-09-30Cons.Ordinary income
Profit before tax¥13.1bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Profit before tax¥12.1bn2021-04-01 → 2021-09-30Cons.Income before income taxes
Net income (owners)¥6.3bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥13.5bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥7.3bn2021-04-01 → 2021-09-30Cons.Profit loss attributable to owners of parent
Net income¥7.1bn2022-04-01 → 2022-09-30Cons.Profit loss
Net income¥8.1bn2021-04-01 → 2021-09-30Cons.Profit loss
Total assets¥1.01Tat 2022-09-30Cons.Assets
Total assets¥930.3bnat 2022-03-31Cons.Assets
Total assets¥888.3bnat 2021-09-30Cons.Total assets (5-year summary)
Total liabilities¥768.6bnat 2022-09-30Cons.Liabilities
Total liabilities¥730.5bnat 2022-03-31Cons.Liabilities
Net assets / equity¥237.2bnat 2022-09-30Cons.Net assets
Net assets / equity¥199.9bnat 2022-03-31Cons.Net assets
Net assets / equity¥190.8bnat 2021-09-30Cons.Net assets (5-year summary)
Cash and deposits¥95.5bnat 2022-09-30Cons.Cash and deposits
Cash and deposits¥95.3bnat 2022-03-31Cons.Cash and deposits
Cash & equivalents¥89.9bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥90.1bnat 2022-03-31Cons.Cash and cash equivalents
Cash & equivalents¥75.0bnat 2021-09-30Cons.Cash and cash equivalents
Cash & equivalents¥85.8bnat 2021-03-31dCons.Cash and cash equivalents
Operating cash flow¥3.7bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥68.2bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥25.5bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥41.3bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥78.4bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥47.4bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in investment activities
Financing cash flow¥23.8bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
Financing cash flow¥10.3bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥7.3bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥38.342022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥5.992022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥82.52021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥44.782021-04-01 → 2021-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥24.542021-07-01 → 2021-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥33.972022-04-01 → 2022-09-30Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥77.422021-04-01 → 2022-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥44.652021-04-01 → 2021-09-30Cons.Diluted earnings per share (5-year summary)
Equity ratio22.0%at 2022-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio19.9%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio19.9%at 2021-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 54
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2022-09-30¥2.1bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2022-09-30¥340m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2022-09-30¥1.8bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2022-09-30¥168m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥18.6bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥18.6bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥15.3bn
jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segmentrevenue2022-04-01 → 2022-09-30¥203.9bn
jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segmentrevenue external2022-04-01 → 2022-09-30¥200.8bn
jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥3.1bn
jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segmentsegment profit2022-04-01 → 2022-09-30¥18.6bn
jpcrp040300-q2r_E02688-000Medicine Relatedreportable segmentrevenue2022-04-01 → 2022-09-30¥44.9bn
jpcrp040300-q2r_E02688-000Medicine Relatedreportable segmentrevenue external2022-04-01 → 2022-09-30¥34.1bn
jpcrp040300-q2r_E02688-000Medicine Relatedreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥10.8bn
jpcrp040300-q2r_E02688-000Medicine Relatedreportable segmentsegment profit2022-04-01 → 2022-09-30¥849m
jpcrp040300-q2r_E02688-000Pharma Packagingreportable segmentrevenue2022-04-01 → 2022-09-30¥28.0bn
jpcrp040300-q2r_E02688-000Pharma Packagingreportable segmentrevenue external2022-04-01 → 2022-09-30¥25.0bn
jpcrp040300-q2r_E02688-000Pharma Packagingreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥3.0bn
jpcrp040300-q2r_E02688-000Pharma Packagingreportable segmentsegment profit2022-04-01 → 2022-09-30¥2.1bn
—segment totalrevenue2022-04-01 → 2022-09-30¥276.8bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥260.0bn
—segment totalrevenue intersegment2022-04-01 → 2022-09-30¥16.8bn
—segment totalsegment profit2022-04-01 → 2022-09-30¥21.5bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-09-30¥278.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-09-30¥260.3bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-09-30¥18.6bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-09-30¥21.7bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2021-04-01 → 2021-09-30¥1.3bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2021-04-01 → 2021-09-30¥295m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2021-04-01 → 2021-09-30¥988m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2021-04-01 → 2021-09-30¥205m
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-09-30−¥17.6bn
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-09-30−¥17.6bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-09-30−¥11.7bn
jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segmentrevenue2021-04-01 → 2021-09-30¥186.8bn
jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segmentrevenue external2021-04-01 → 2021-09-30¥183.4bn
jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥3.3bn
jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segmentsegment profit2021-04-01 → 2021-09-30¥19.6bn
jpcrp040300-q2r_E02688-000Medicine Relatedreportable segmentrevenue2021-04-01 → 2021-09-30¥45.2bn
jpcrp040300-q2r_E02688-000Medicine Relatedreportable segmentrevenue external2021-04-01 → 2021-09-30¥35.0bn
jpcrp040300-q2r_E02688-000Medicine Relatedreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥10.2bn
jpcrp040300-q2r_E02688-000Medicine Relatedreportable segmentsegment profit2021-04-01 → 2021-09-30¥2.6bn
jpcrp040300-q2r_E02688-000Pharma Packagingreportable segmentrevenue2021-04-01 → 2021-09-30¥26.5bn
jpcrp040300-q2r_E02688-000Pharma Packagingreportable segmentrevenue external2021-04-01 → 2021-09-30¥23.4bn
jpcrp040300-q2r_E02688-000Pharma Packagingreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥3.1bn
jpcrp040300-q2r_E02688-000Pharma Packagingreportable segmentsegment profit2021-04-01 → 2021-09-30¥2.1bn
—segment totalrevenue2021-04-01 → 2021-09-30¥258.4bn
—segment totalrevenue external2021-04-01 → 2021-09-30¥241.8bn
—segment totalrevenue intersegment2021-04-01 → 2021-09-30¥16.6bn
—segment totalsegment profit2021-04-01 → 2021-09-30¥24.3bn
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-09-30¥259.7bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-09-30¥242.1bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-09-30¥17.6bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-09-30¥24.5bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 643
ItemContextValueUnit
Deferred tax assetsCurrentQuarterInstant13879000000JPY
Other ioaPrior1YearInstant31052000000JPY
Other ioaCurrentQuarterInstant31600000000JPY
Allowance for doubtful accounts ioa by groupPrior1YearInstant-6154000000JPY
Allowance for doubtful accounts ioa by groupCurrentQuarterInstant-5935000000JPY
Investments and other assetsPrior1YearInstant82299000000JPY
Investments and other assetsCurrentQuarterInstant81180000000JPY
Noncurrent assetsPrior1YearInstant492862000000JPY
Noncurrent assetsCurrentQuarterInstant530087000000JPY
AssetsPrior1YearInstant930321000000JPY
AssetsCurrentQuarterInstant1005719000000JPY
Notes and accounts payable tradePrior1YearInstant73544000000JPY
Notes and accounts payable tradeCurrentQuarterInstant77511000000JPY
Short term loans payablePrior1YearInstant150675000000JPY
Short term loans payableCurrentQuarterInstant166761000000JPY
Current portion of bondsPrior1YearInstant2200000000JPY
Current portion of bondsCurrentQuarterInstant2100000000JPY
Lease obligations clPrior1YearInstant3885000000JPY
Lease obligations clCurrentQuarterInstant4244000000JPY
Accounts payable otherPrior1YearInstant24601000000JPY
Accounts payable otherCurrentQuarterInstant20825000000JPY
Income taxes payablePrior1YearInstant5528000000JPY
Income taxes payableCurrentQuarterInstant6486000000JPY
Advances receivedPrior1YearInstant2115000000JPY
Advances receivedCurrentQuarterInstant705000000JPY
Unearned revenuePrior1YearInstant284000000JPY
Unearned revenueCurrentQuarterInstant377000000JPY
Provision for bonusesPrior1YearInstant5239000000JPY
Provision for bonusesCurrentQuarterInstant8879000000JPY
Provision for directors bonusesPrior1YearInstant166000000JPY
Provision for directors bonusesCurrentQuarterInstant3000000JPY
Provision for loss on disaster clPrior1YearInstant130000000JPY
Provision for loss on disaster clCurrentQuarterInstant81000000JPY
Notes payable facilitiesPrior1YearInstant5882000000JPY
Notes payable facilitiesCurrentQuarterInstant5485000000JPY
Other clPrior1YearInstant37738000000JPY
Other clCurrentQuarterInstant40243000000JPY
Current liabilitiesPrior1YearInstant311993000000JPY
Current liabilitiesCurrentQuarterInstant333705000000JPY
Bonds payablePrior1YearInstant78700000000JPY
Bonds payableCurrentQuarterInstant77700000000JPY
Convertible bond type bonds with subscription rights to sharesPrior1YearInstant30270000000JPY
Convertible bond type bonds with subscription rights to sharesCurrentQuarterInstant30240000000JPY
Long term loans payablePrior1YearInstant267614000000JPY
Long term loans payableCurrentQuarterInstant285463000000JPY
Lease obligations nclPrior1YearInstant25626000000JPY
Lease obligations nclCurrentQuarterInstant25076000000JPY
Deferred tax liabilitiesPrior1YearInstant617000000JPY
Deferred tax liabilitiesCurrentQuarterInstant763000000JPY
Net defined benefit liabilityPrior1YearInstant5927000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identityconsolidated 2022-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass